ARGENT BIOPHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.405 AUD | +5.19% |
|
+2.53% | -14.74% |
| May. 07 | Argent BioPharma Reports CFO Appointment | MT |
| May. 07 | Argent BioPharma shares begin trading on OTCQB Venture Market | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 4.73M 3.13M | Sales 2023 | 3.39M 2.24M | Capitalization | 16.75M 11.07M |
|---|---|---|---|---|---|
| Net income 2022 | -20M -13.21M | Net income 2023 | -20M -13.21M | EV / Sales 2022 | 9.75 x |
| Net Debt 2022 | 2.47M 1.63M | Net Debt 2023 | 9.51M 6.29M | EV / Sales 2023 | 7.75 x |
| P/E ratio 2022 |
-2.02
x | P/E ratio 2023 |
-0.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 9.44% |
More Fundamentals
* Assessed data
More news
| 1 week | +6.58% | ||
| Current month | -1.22% | ||
| 1 month | -2.41% | ||
| 3 months | +1.25% | ||
| 6 months | -38.64% | ||
| Current year | -14.74% |
1 week
0.37
0.41
1 month
0.370.45
3 years
0.3067.00
5 years
0.30130.00
10 years
0.30130.00
| Managers | Title | Age | Since |
|---|---|---|---|
Roby Zomer
FOU | Founder | 44 | 05-10-20 |
Yifat Steuer
COO | Chief Operating Officer | 53 | 22-10-03 |
Nadya Lisovoder
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roby Zomer
FOU | Founder | 44 | 05-10-20 |
| Director/Board Member | - | 23-05-31 | |
Daniel Robinson
BRD | Director/Board Member | - | Nov. 30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.405 | +5.19% | 2 089 |
| 24-05-09 | 0.385 | +1.32% | 529 |
| 24-05-08 | 0.38 | -3.80% | 5,582 |
| 24-05-07 | 0.395 | +3.95% | 967 |
| 24-05-06 | 0.38 | 0.00% | 2,801 |
Delayed Quote Australian S.E., May 10, 2024 at 02:10 am EDT
More quotes
Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.09% | 6.3B | |
| -16.34% | 4.53B | |
| -7.11% | 3.29B | |
| +5.14% | 3.2B | |
| -0.18% | 2.63B | |
| +47.93% | 1.97B | |
| -7.15% | 1.74B | |
| +0.67% | 1.69B | |
| -8.73% | 1.64B |
- Stock Market
- Equities
- RGT Stock
- MXC Stock